Organon & Co. — Company profile
Healthcare · Drug Manufacturers - General · United States
Last price 13.81 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 3.63B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women’s health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon to prevent pregnancy; Follistim AQ, which is used to promote development of ovarian follicles; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products to control and prevent asthma symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.
Details
| Name | Organon & Co. |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Employees | 10000 |
| Founded | 1923 |
| Ceo | Joseph Morrissey |
| Country | United States |
| Exchange | NYSE |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US68622V1061 |
| Cusip | 68622V106 |
| Cik | 1821825 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Joseph T. Morrissey Jr. | Chief Executive Officer |
| Carrie Smith Cox | Executive Chair of the Board |
| Matthew M. Walsh C.F.A. | Executive Vice President and Chief Financial Officer |
| Rachel A. Stahler | Executive Vice President, Chief Information Officer and Chief Digital and Growth Officer |
| Kirke Weaver | Executive Vice President, General Counsel and Corporate Secretary |
| Dr. Juan Camilo Arjona Ferreira M.D. | Executive Vice President, Head of Research and Development and Chief Medical Officer |
| Jennifer Halchak | Head of Investor Relations |
| Daniel Karp | Chief Strategy Officer and Head of Corporate Development |
| Aaron Falcione | Executive Vice President and Chief Human Resources Officer |
| Vittorio Nisita | Executive Vice President and Head of Enterprise Services and Solutions |
Contact
| Address | 30 Hudson Street, Floor 33, Jersey City, New Jersey 07302, United States |
| Phone | 551 430 6900 |
| Website | https://www.organon.com |